Achillion Granted Twentieth Patent for Factor D Portfolio
May 14 2019 - 6:00AM
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ),
a clinical-stage biopharmaceutical company dedicated to
transforming the lives of patients and families affected by
complement-mediated diseases, today announced that the U.S. Patent
and Trademark Office (USPTO) issued U.S. Patent #10,287,301 to
Achillion for ACH-5548, its next-generation orally administered
complement factor D small molecule inhibitor product candidate.
This patent covers the composition of matter of ACH-5548, and a
pharmaceutical composition that includes ACH-5548, a key mediator
in the complement alternative pathway (AP). This issued patent will
be the twentieth patent that the USPTO has granted to Achillion for
its complement factor D portfolio of small molecules. Achillion
currently has over one hundred global patent applications and
patents including the composition of matter and method of use for
its complement-related research program.
“Our intellectual property estate continues to
yield issued patents stemming from our pioneering efforts in the
discovery and development of oral small molecule factor D
inhibitors, both in the United States and foreign countries.
Achillion now has issued U.S. patents claiming the composition of
matter for all three of its clinical development compounds,
ACH-4471, ACH-5228 and ACH-5548,” commented Joseph Truitt,
President and Chief Executive Officer of Achillion. “We believe
this extensive patent portfolio provides a foundation to support
the broader application of our factor D inhibitors in hematology
and nephrology and potentially other therapeutic areas including
ophthalmology and neurology.”
About the Achillion Complement Factor D
Portfolio
Achillion has leveraged its internal discovery
capabilities and a novel complement-related platform to develop
oral small molecule drug candidates that are inhibitors of
complement factor D. Factor D is an essential serine protease
involved in the AP of the complement system, a part of the innate
immune system. Achillion's complement platform is focused on
seeking to advance oral small molecules that inhibit the AP and can
potentially be used in the treatment of immune-related diseases in
which complement AP plays a critical role. Potential indications
currently being evaluated for these compounds include paroxysmal
nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune
complex-mediated membranoproliferative glomerulonephritis
(IC-MPGN).
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on
advancing its oral small molecule complement inhibitors
into late-stage development and commercialization. Research
has shown that an overactive complement system plays a critical
role in multiple disease conditions including the therapeutic areas
of nephrology, hematology, ophthalmology and neurology. Achillion
is initially focusing its drug development activities on
complement-mediated diseases where there are no approved therapies
or where existing therapies are inadequate for patients. Potential
indications being evaluated for its compounds include paroxysmal
nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune
complex membranoproliferative glomerulonephritis (IC-MPGN). Each of
the product candidates in the Company’s oral small molecule
portfolio was discovered in its laboratories and is wholly
owned. To advance its investigational product candidates into
Phase 3 clinical trials and commercialization, the Company plans to
work closely with key stakeholders including healthcare
professionals, patients, regulators and payors. More information is
available at Achillion’s website www.achillion.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks, uncertainties and
other important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements.
Achillion may use words such as “expect,” “anticipate,” “project,”
“target,” “intend,” “plan,” “aim,” “believe,” “seek,” “estimate,”
“can,” “could” “focus,” “will,” “look forward,” “continue,” “goal,”
“strategy,” “objective,” “may,” “potential,” and similar
expressions to identify such forward-looking statements. These
forward-looking statements also include statements about: the
expected advantages and benefits of the Company’s patent portfolio;
the potential benefits of factor D inhibition as a treatment for
complement-mediated diseases; the potential benefits of, and
indications for, Achillion’s compounds that inhibit factor D,
including ACH-4471, ACH-5228 and ACH-5548; and other statements
concerning Achillion’s strategic goals, efforts, plans, and
prospects. Among the important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are risks relating to, among other
things, Achillion’s ability to: demonstrate in any current and
future clinical trials the requisite safety, efficacy and
combinability of its product candidates; advance the preclinical
and clinical development of its complement factor D inhibitors
under the timelines it projects in current and future preclinical
studies and clinical trials; enroll patients in its clinical trials
on its projected timelines; replicate in later stage clinical
trials favorable data demonstrated in preclinical and early- stage
clinical trials; obtain and maintain patent protection for its
product candidates and the freedom to operate under third party
intellectual property; obtain and maintain necessary regulatory
approvals, and the granting of orphan designation does not alter
the standard regulatory requirements and process for obtaining such
approval; establish commercial manufacturing arrangements;
identify, enter into and maintain collaboration and other
commercial agreements with third-parties; compete successfully in
the markets in which it seeks to develop and commercialize its
product candidates and future products; manage expenses; manage
litigation; raise the substantial additional capital needed to
achieve its business objectives; and successfully execute on its
business strategies. These and other risks are described in the
reports filed by Achillion with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2018, and any other SEC filings that
Achillion makes from time to time.
In addition, any forward-looking statement in
this press release represents Achillion's views only as of the date
of this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Investors: Brian Di Donato Senior VP, Chief
Financial OfficerTel. (215) 709-3032 bdidonato@achillion.com
Media:Susanne HeinzingerSenior VP, Corporate
CommunicationsTel. (215) 709-3055sheinzinger@achillion.com
Source: Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024